BioSpace News Archive

Apollo Medical Holdings, Inc., a leading physician-centric, technology-powered healthcare management company, and CAIPA MSO, LLC, a management services organization based out of New York, announced a strategic alliance and investment by ApolloMed in CAIPA MSO.

Interrad Medical, a privately held medical device company, announces significant statements regarding use of SecurAcath in the recently published Infusion Therapy Standards of Care, 8th Edition.

Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol ® Cyclo™, at WORLD Symposium 2021

— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line data in 643 subject Alzheimer’s disease pivotal GAIN Trial on schedule to be announced in Q4 2021

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, has recently been issued U.S. Patent 10898166 from the United States Patent & Trademark Office.

Novamind Inc., a mental health company specialized in psychedelic medicine, announces that is has entered into marketing services agreements with Octagon Media Corp., AGORA Internet Relations Corp, and a consulting agreement with Venture North Capital Inc.

Ovation Science Inc. is pleased to announce it has received a further order for its DermSafe® hand sanitizer lotion from its distributor, Grupo Venta International, S.A. de C.V., with corporate offices in Guadalajara, Mexico.

The acquisition is intended to vertically integrate the Companys retail manufacturing capabilities to support the growth of its nutraceutical division and deliver unique products to consumers

Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, announced today that it has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.

Jan. 26, 2021 13:04 UTC Company has supplied over 30 million doses to U.S. Government to date Remains on track to deliver 100 million doses to the U.S. Government by end of March 2021 Remains on track to deliver 200 million doses to the U.S. Government by end of June 2021 CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided a supply update for the